Evidence map›Paper›PMID 32409565›Full record

ArticleJournal of cell science2020

TDP-43, a protein central to amyotrophic lateral sclerosis, is destabilized by tankyrase-1 and -2.

Leeanne McGurk, Olivia M Rifai, Nancy M Bonini

Open access · hybridAbstract read
In one paragraph

Article in Journal of cell science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Aberrant NSUN1 activity connects mLife science alliance · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Altered Phase Separation and Cellular Impact inFrontiers in cellular neuroscience · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leeanne McGurkDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA LMcgurk001@dundee.ac.uk nbonini@sas.upenn.edu.ORCID 0000-0002-6493-6751
Olivia M RifaiDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-0996-1110
Nancy M BoniniDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA LMcgurk001@dundee.ac.uk nbonini@sas.upenn.edu.ORCID 0000-0003-0226-5291
University of Pennsylvania · US

Funding

Molecular Genetic Insight into Neurodegenerative Disease from DrosophilaR35NS097275 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BONINI, NANCY M · 2017 to 2024
$6.0M
Ataxin-2 as a genetic risk factor for ALS: New insights into neurodegenerationR01NS073660 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BONINI, NANCY M, GITLER, AARON D. · 2011 to 2015
$1.7M
NINDS NIH HHS R01 NS073660NINDS NIH HHS R35 NS097275
6 · The paper itself

Abstract

In >95% of cases of amyotrophic lateral sclerosis (ALS) and ∼45% of frontotemporal degeneration (FTD), the RNA/DNA-binding protein TDP-43 is cleared from the nucleus and abnormally accumulates in the cytoplasm of affected brain cells. Although the cellular triggers of disease pathology remain enigmatic, mounting evidence implicates the poly(ADP-ribose) polymerases (PARPs) in TDP-43 neurotoxicity. Here we show that inhibition of the PARP enzymes tankyrase 1 and tankyrase 2 (referred to as Tnks-1/2) protect primary rodent neurons from TDP-43-associated neurotoxicity. We demonstrate that Tnks-1/2 interacts with TDP-43 via a newly defined tankyrase-binding domain. Upon investigating the functional effect, we find that interaction with Tnks-1/2 inhibits the ubiquitination and proteasomal turnover of TDP-43, leading to its stabilization. We further show that proteasomal turnover of TDP-43 occurs preferentially in the nucleus; our data indicate that Tnks-1/2 stabilizes TDP-43 by promoting cytoplasmic accumulation, which sequesters the protein from nuclear proteasome degradation. Thus, Tnks-1/2 activity modulates TDP-43 and is a potential therapeutic target in diseases associated with TDP-43, such as ALS and FTD.This article has an associated First Person interview with the first author of the paper.

Indexed as

Amyotrophic Lateral SclerosisTankyrasesCell NucleusCytoplasmDNA-Binding ProteinsHumansDNA-Binding ProteinsTankyrasesTARDBP protein, humanALSFTDPARPPoly(ADP-ribose)ProteasomeUbiquitin

Identifiers

PMID32409565
PMCPMC7328137
OpenAlexW3025696271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.